Drug

Amlexanox

In clinical development

ClassPhosphodiesterase 4 inhibitorEmerging researchEarly-to-mid development

Also known as Amoxanox, Aphthasol, Amlexanoxo, 2-Amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3-b)pyridine-3-carboxylic acid+1 more

Amoxanox, Aphthasol, Amlexanoxo, 2-Amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3-b)pyridine-3-carboxylic acid, Amlexanoxum.

RxNorm46307 ChEMBLCHEMBL1096 ATCA01AD07 ATCR03DX01UNIIBRL1C2459K

Research papers

Protein targets

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A phosphodiesterase 4 (PDE4) inhibitor, amlexanox, reduces neuroinflammation and neuronal death after pilocarpine-induced seizure.

Research2024-04-16Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Clinical Protocol to Investigate the Efficacy of Amlexanox vs. Placebo for Treatment of Glucose and Lipid Abnormalities in Obese Type 2 Diabetics

Clinical trial2018-11-07Results posted · ClinicalTrials.gov

Clinical Protocol to Investigate the Efficacy of Amlexanox for Treatment of Glucose and Lipid Abnormalities in Obese Type 2 Diabetics

Clinical trial2014-02-25Terminated · ClinicalTrials.gov

A Double-blind, Randomized, Vehicle-controlled Phase II Study to Determine the Effects of Concomitant Treatment With Amlexanox 0.5% Oral Rinse Solution on Oral Mucositis Associated With Radiation Therapy for Cancer of the Head and Neck Region

Clinical trial2001-06-01Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Amlexanox

Aliases & brands

AmoxanoxAphthasolAmlexanoxo2-Amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3-b)pyridine-3-carboxylic acidAmlexanoxum

RxNorm CUI

46307

ChEMBL ID

CHEMBL1096

ATC codes

A01AD07R03DX01

UNII

BRL1C2459K

Primary mechanism

Phosphodiesterase 4 inhibitor

Pharmacology & targets

4 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

3',5'-cyclic-AMP phosphodiesterase 4A

PDE4A · P27815

INHIBITORPhosphodiesterase 4 inhibitor

3',5'-cyclic-AMP phosphodiesterase 4D

PDE4D · Q08499

INHIBITORPhosphodiesterase 4 inhibitor

3',5'-cyclic-AMP phosphodiesterase 4B

PDE4B · Q07343

INHIBITORPhosphodiesterase 4 inhibitor

3',5'-cyclic-AMP phosphodiesterase 4C

PDE4C · Q08493

INHIBITORPhosphodiesterase 4 inhibitor

Clinical trials

3 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2017

Completed

Discontinued

PHASE DISTRIBUTIONn = 3

Phase 23

Recent completions

Trials that read out recently, adding to the completed evidence base.

Clinical Protocol to Investigate the Efficacy of Amlexanox vs. Placebo for Treatment of Glucose and Lipid Abnormalities in Obese Type 2 Diabetics

CompletedPH IIUniversity of Michigann=422017

CompletedPH IIAccess Pharmaceuticals, Inc.n=582001

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

A phosphodiesterase 4 (PDE4) inhibitor, amlexanox, reduces neuroinflammation and neuronal death after pilocarpine-induced seizure.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024 · 14 cites

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Pilocarpine

Studied across 2 of the same disease areas as Amlexanox in the shared literature.

2 shared diseases1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials